HCW BIOLOGICS INC
HCWBNASDAQTrading Snapshot
- Day Range
- $1.77 β $1.81
- 52-Week Range
- $1.50 β $29.28
- Volume
- $3.05B
- Avg Volume
- $2.15B
- Shares Outstanding
- 347,641
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $54,232
- Last Q Revenue
- $135,568
- P/E Ratio
- -0.0
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-14.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β94.6%
Why Investors Own HCWB
- βHigh-growth profile β revenue up +58.1% YoY with expanding US Equity exposure.
- βHealthy economics β 63% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
HCW BIOLOGICS INC
HCWB
StockOtter Β· stockotter.spaceAbout HCW BIOLOGICS INC
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
HCW Biologics Announces Pricing of $1.5 Million Private Placement
MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the βCompanyβ or βHCW Biologicsβ), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to t
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia area
HCW Biologics' TGF-Ξ² Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
Human studies show that the TGF-Ξ² trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-Ξ²/IL-15 moiety into the constructs of its second-generation
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the βCompanyβ or βHCW Biologicsβ) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeu
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the βCompanyβ or βHCW Biologicsβ), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to tr